Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.87
INFI's Cash-to-Debt is ranked lower than
62% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. INFI: 3.87 )
Ranked among companies with meaningful Cash-to-Debt only.
INFI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28  Med: 493.15 Max: 13254
Current: 3.87
0.28
13254
Piotroski F-Score: 3
Altman Z-Score: -5.91
Beneish M-Score: -0.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3.20
INFI's Operating Margin % is ranked lower than
52% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. INFI: -3.20 )
Ranked among companies with meaningful Operating Margin % only.
INFI' s Operating Margin % Range Over the Past 10 Years
Min: -164.99  Med: -91.69 Max: 22.94
Current: -3.2
-164.99
22.94
Net Margin % 0.47
INFI's Net Margin % is ranked lower than
53% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. INFI: 0.47 )
Ranked among companies with meaningful Net Margin % only.
INFI' s Net Margin % Range Over the Past 10 Years
Min: -160.77  Med: -68.67 Max: 28.35
Current: 0.47
-160.77
28.35
ROE % -1.10
INFI's ROE % is ranked higher than
51% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. INFI: -1.10 )
Ranked among companies with meaningful ROE % only.
INFI' s ROE % Range Over the Past 10 Years
Min: -123.36  Med: -33.2 Max: 27.59
Current: -1.1
-123.36
27.59
ROA % 0.05
INFI's ROA % is ranked higher than
64% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. INFI: 0.05 )
Ranked among companies with meaningful ROA % only.
INFI' s ROA % Range Over the Past 10 Years
Min: -44.77  Med: -21.57 Max: 16.29
Current: 0.05
-44.77
16.29
ROC (Joel Greenblatt) % 5.26
INFI's ROC (Joel Greenblatt) % is ranked higher than
62% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. INFI: 5.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INFI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3156.78  Med: -543.5 Max: 418.86
Current: 5.26
-3156.78
418.86
3-Year EBITDA Growth Rate -42.00
INFI's 3-Year EBITDA Growth Rate is ranked lower than
88% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INFI: -42.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INFI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: 4.45 Max: 135.8
Current: -42
-55.4
135.8
3-Year EPS without NRI Growth Rate -38.60
INFI's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. INFI: -38.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INFI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64  Med: 12.3 Max: 116
Current: -38.6
-64
116
GuruFocus has detected 3 Warning Signs with Infinity Pharmaceuticals Inc $INFI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INFI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

INFI Guru Trades in Q2 2016

Jim Simons 749,700 sh (+5995.12%)
Paul Tudor Jones 277,600 sh (+365.77%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q3 2016

INFI Guru Trades in Q3 2016

Jim Simons 1,860,900 sh (+148.22%)
Paul Tudor Jones 19,798 sh (-92.87%)
» More
Q4 2016

INFI Guru Trades in Q4 2016

Paul Tudor Jones 165,998 sh (+738.46%)
Jim Simons 1,700,000 sh (-8.65%)
» More
Q1 2017

INFI Guru Trades in Q1 2017

Paul Tudor Jones Sold Out
Jim Simons 1,439,241 sh (-15.34%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARQL, NAS:VSTM, NAS:NEPT, NAS:CBMG, NAS:OPHT, OTCPK:CYDY, NAS:BLRX, OTCPK:NURPF, NAS:AVEO, OTCPK:MTFBF, AMEX:ATNM, NAS:MRTX, NAS:NTEC, NAS:AXSM, OTCPK:PTGEF, OTCPK:MCUJF, NAS:NVET, NAS:NOVN, NAS:LIFE, NAS:SVRA » details
Traded in other countries:I3F.Germany,
Headquarter Location:USA
Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its product candidate is duvelisib, also known as IPI-145, an oral inhibitor.

Infinity is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products, and those under development, include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology-related treatments.

Top Ranked Articles about Infinity Pharmaceuticals Inc

Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.18
INFI's PB Ratio is ranked higher than
75% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. INFI: 1.18 )
Ranked among companies with meaningful PB Ratio only.
INFI' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.11 Max: 51.43
Current: 1.18
0.45
51.43
PS Ratio 9.01
INFI's PS Ratio is ranked higher than
67% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. INFI: 9.01 )
Ranked among companies with meaningful PS Ratio only.
INFI' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 4.13 Max: 60.95
Current: 9.01
0.55
60.95
EV-to-EBIT 23.60
INFI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. INFI: 23.60 )
Ranked among companies with meaningful EV-to-EBIT only.
INFI' s EV-to-EBIT Range Over the Past 10 Years
Min: -161.2  Med: -2.7 Max: 94.2
Current: 23.6
-161.2
94.2
EV-to-EBITDA 6.52
INFI's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. INFI: 6.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
INFI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -862.7  Med: -2.9 Max: 26.1
Current: 6.52
-862.7
26.1
Current Ratio 7.59
INFI's Current Ratio is ranked higher than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. INFI: 7.59 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 8.32 Max: 17.81
Current: 7.59
0.64
17.81
Quick Ratio 7.59
INFI's Quick Ratio is ranked higher than
54% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INFI: 7.59 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 8.3 Max: 17.81
Current: 7.59
0.41
17.81
Days Sales Outstanding 1.66
INFI's Days Sales Outstanding is ranked higher than
97% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. INFI: 1.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 2.82 Max: 75.87
Current: 1.66
0.18
75.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
INFI's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. INFI: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INFI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.7  Med: -10.5 Max: -0.8
Current: -1.5
-178.7
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.91
INFI's Price-to-Net-Cash is ranked higher than
73% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. INFI: 1.91 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INFI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.85  Med: 2.87 Max: 38.43
Current: 1.91
0.85
38.43
Price-to-Net-Current-Asset-Value 1.72
INFI's Price-to-Net-Current-Asset-Value is ranked higher than
78% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. INFI: 1.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INFI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.74  Med: 2.69 Max: 398.67
Current: 1.72
0.74
398.67
Price-to-Tangible-Book 1.18
INFI's Price-to-Tangible-Book is ranked higher than
80% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INFI: 1.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INFI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 2.21 Max: 46.18
Current: 1.18
0.55
46.18
Price-to-Median-PS-Value 2.18
INFI's Price-to-Median-PS-Value is ranked lower than
84% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. INFI: 2.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INFI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.75 Max: 14.47
Current: 2.18
0.13
14.47
Earnings Yield (Greenblatt) % 4.24
INFI's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. INFI: 4.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INFI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 73 Max: 8304.4
Current: 4.24
1.1
8304.4

More Statistics

Revenue (TTM) (Mil) $18.72
EPS (TTM) $ -0.01
Beta2.60
Short Percentage of Float8.51%
52-Week Range $0.84 - 5.79
Shares Outstanding (Mil)50.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 90 55
EPS ($) -1.34 -0.76 -0.76
EPS without NRI ($) -1.34 -0.76 -0.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INFI

Headlines

Articles On GuruFocus.com
Infinity Provides Company Update and Reports First Quarter 2017 Financial Results May 09 2017 
Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast Apr 26 2017 
Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017 Apr 01 2017 
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
Edited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017
Infinity reports 1Q loss May 09 2017
Infinity Provides Company Update and Reports First Quarter 2017 Financial Results May 09 2017
Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance May 09 2017
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed May 09 2017
Investor Network: Infinity Pharmaceuticals, Inc. to Host Earnings Call May 09 2017
Catalent (CTLT) Shows Strength: Stock Adds 9.8% in Session May 08 2017
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 May 05 2017
Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss Apr 28 2017
Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast Apr 26 2017
ETFs with exposure to Infinity Pharmaceuticals, Inc. : April 19, 2017 Apr 19 2017
Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III Apr 19 2017
Why Is Infinity (INFI) Down 37.4% Since the Last Earnings Report? Apr 19 2017
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19% Apr 18 2017
Today's Research Reports on Biotech Stocks to Watch: Cleveland BioLabs and Infinity Pharmaceuticals Apr 18 2017
Bio-Path Holdings (BPTH) Looks Good: Stock Moves 13% Higher Apr 17 2017
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549 Apr 10 2017
New Strong Buy Stocks for April 10th Apr 10 2017
Cardiome Pharma (CRME) Jumps: Stock Adds 6.6% in Session Apr 10 2017
Ismailia National Food Industries : Neutral assessment on price but strong on fundamentals Apr 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)